Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: OZEMPIC
Published 2026-02-05 · Last reviewed 2026-02-12 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Ozempic is a once-weekly injectable form of semaglutide, a GLP-1 receptor agonist indicated for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease (label).
It is not a psychiatric medication. In psychiatric practice, GLP-1 therapies are most often discussed when metabolic disease (obesity, prediabetes/diabetes) complicates care or when weight-gain–promoting psychotropics create cardiometabolic risk (clinical).
Evidence for GLP-1 therapy in antipsychotic-associated metabolic dysfunction is strongest for the class overall (including a randomized trial with liraglutide in clozapine/olanzapine-treated schizophrenia spectrum patients) rather than for any single product, and care is often coordinated with primary care/endocrinology (JAMA/clinical).
The compare view, evidence feed, and print page help track dosing/titration and key safety monitoring themes.
Access is frequently shaped by insurance coverage and by whether diabetes and cardiovascular indications are present. In psychiatric populations, the operational work (coordination, prior authorizations, education, and follow-up) often determines feasibility as much as efficacy (clinical).
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Semaglutide is a GLP-1 receptor agonist. GLP-1 activity increases glucose-dependent insulin secretion, suppresses inappropriate glucagon, and slows gastric emptying; clinically it also reduces appetite and supports weight loss (label/clinical).
In mental health care, the most common rationale is metabolic: reducing obesity/diabetes burden that increases cardiovascular risk and can limit psychotropic options (clinical).
Consider coordination with primary care/endocrinology for diabetes regimen changes, cardiovascular risk management, and screening frequency decisions (clinical).